Brogdon Jennifer L, Xu Yongyao, Szabo Susanne J, An Shaojian, Buxton Francis, Cohen Dalia, Huang Qian
Department of Developmental & Molecular Pathways, Novartis Institute for BioMedical Research, Cambridge, MA 02138, USA.
Blood. 2007 Feb 1;109(3):1123-30. doi: 10.1182/blood-2006-04-019711. Epub 2006 Sep 28.
Histone deacetylases (HDACs) play a critical role in regulating gene expression and key biological processes. However, how HDACs are involved in innate immunity is little understood. Here, in this first systematic investigation of the role of HDACs in immunity, we show that HDAC inhibition by a small-molecule HDAC inhibitor (HDACi), LAQ824, alters Toll-like receptor 4 (TLR4)-dependent activation and function of macrophages and dendritic cells (DCs). Surprisingly, pan-HDAC inhibition modulates only a limited set of genes involved in distinct arms of immune responses. Specifically, it inhibited DC-controlled T helper 1 (Th1) effector but not Th2 effector cell activation and migration. It also inhibited macrophage- and DC-mediated monocyte but not neutrophil chemotaxis. These unexpected findings demonstrate the high specificity of HDAC inhibition in modulating innate and adaptive immune responses, and highlight the potential for HDACi to alter the Th1 and Th2 balance in therapeutic settings.
组蛋白去乙酰化酶(HDACs)在调节基因表达和关键生物学过程中发挥着关键作用。然而,人们对HDACs如何参与先天免疫了解甚少。在此,在对HDACs在免疫中的作用进行的首次系统性研究中,我们发现小分子HDAC抑制剂(HDACi)LAQ824对HDAC的抑制作用会改变Toll样受体4(TLR4)依赖性巨噬细胞和树突状细胞(DCs)的激活及功能。令人惊讶的是,泛HDAC抑制仅调节参与不同免疫反应分支的有限一组基因。具体而言,它抑制DC控制的辅助性T细胞1(Th1)效应细胞,但不抑制Th2效应细胞的激活和迁移。它还抑制巨噬细胞和DC介导的单核细胞趋化性,但不抑制中性粒细胞趋化性。这些意外发现证明了HDAC抑制在调节先天和适应性免疫反应中的高度特异性,并突出了HDACi在治疗环境中改变Th1和Th2平衡的潜力。